Robert Hindes MD
15 SlideShares 2 Followers
Personal Information
Unternehmen/Arbeitsplatz
Danbury, Connecticut United States
Beruf
Vice President, Clinical Development
Branche
Medical / Health Care / Pharmaceuticals
Webseite
about.me/roberthindes
Info
A medical professional with over 20 years of experience in the field of infectious diseases, Dr. Robert Hindes is an author of more than 70 peer-reviewed articles and abstracts since 1984. Dr. Robert Hindes also holds the status of Diplomate with the American Board of Internal Medicine, with a sub-specialty in infectious diseases. More recently, Dr. Robert Hindes served as Vice President of Clinical Development with Pharmasset, Inc., which is based in Princeton, New Jersey. Dr. Hindes held this position for almost a year until Gilead Sciences purchased Pharmasset in January 2012, when he served in a transitional capacity as Vice President of Clinical Research for Gilead.
Kontaktdetails
Tags
robert hindes md hepatitis c robert hindes md trek therapeutics clinical trials phases hcv treatments sofosbuvir chronic pain non-opioid treatment options reduce opioid reliance opioid reliance revolutionary chronic pain treatment rtx conneticut pharmasset pharmacovigilance program world health organization public-benefit corporation ribavirin hcv treatment peginterferon liver damage cost of a cure cost of hcv drugs hcv new therapy patients hcv and hiv co-infection new hcv treatments financial feasibility natco pharma gilead generic hcv drugs american liver foundation liver life walks world hepatitis day is on july 28 get the numbers behind hcv bms foundation hepatitis care china india hcvm benefits health research gs-7977 study treatment about developing world virus treatment
Mehr anzeigen

Präsentationen

(15)
Alle anzeigen

Sofosbuvir Inhibitor Helps Fight Hepatitis C

Vor 10 Jahren • 1523 Aufrufe

Research Examines Combination Treatment for Hepatitis C

Vor 10 Jahren • 203 Aufrufe

American Liver Foundation Rallies Support for Liver Life Walks

Vor 8 Jahren • 367 Aufrufe

The Co-Infection of HCV and HIV

Vor 8 Jahren • 164 Aufrufe

A New Therapy May Help Patients with HCV

Vor 8 Jahren • 267 Aufrufe

Robert Hindes MD - Trek comprehensive confidential investor ak4 deck 2016

Vor 8 Jahren • 288 Aufrufe

What Are the Different Phases of Clinical Trials?

Vor 7 Jahren • 370 Aufrufe

Trek Therapeutics' Work as a Public-Benefit Corporation

Vor 7 Jahren • 54 Aufrufe

The Work of Trek Pharmaceuticals

Vor 7 Jahren • 48 Aufrufe

The World Health Organization’s Pharmacovigilance Program

Vor 7 Jahren • 110 Aufrufe

Pharmasset

Vor 6 Jahren • 408 Aufrufe

Preventing the Transmission of Hepatitis C

Vor 5 Jahren • 25 Aufrufe

RTX – Revolutionary Chronic Pain Treatment May Reduce Opioid Reliance

Vor 4 Jahren • 22 Aufrufe

What Non-Opioid Treatment Options are Available for Chronic Pain?

Vor 4 Jahren • 44 Aufrufe

The Four Phases of Clinical Trials Before Market Approval

Vor 4 Jahren • 69 Aufrufe
Personal Information
Unternehmen/Arbeitsplatz
Danbury, Connecticut United States
Beruf
Vice President, Clinical Development
Branche
Medical / Health Care / Pharmaceuticals
Webseite
about.me/roberthindes
Info
A medical professional with over 20 years of experience in the field of infectious diseases, Dr. Robert Hindes is an author of more than 70 peer-reviewed articles and abstracts since 1984. Dr. Robert Hindes also holds the status of Diplomate with the American Board of Internal Medicine, with a sub-specialty in infectious diseases. More recently, Dr. Robert Hindes served as Vice President of Clinical Development with Pharmasset, Inc., which is based in Princeton, New Jersey. Dr. Hindes held this position for almost a year until Gilead Sciences purchased Pharmasset in January 2012, when he served in a transitional capacity as Vice President of Clinical Research for Gilead.
Tags
robert hindes md hepatitis c robert hindes md trek therapeutics clinical trials phases hcv treatments sofosbuvir chronic pain non-opioid treatment options reduce opioid reliance opioid reliance revolutionary chronic pain treatment rtx conneticut pharmasset pharmacovigilance program world health organization public-benefit corporation ribavirin hcv treatment peginterferon liver damage cost of a cure cost of hcv drugs hcv new therapy patients hcv and hiv co-infection new hcv treatments financial feasibility natco pharma gilead generic hcv drugs american liver foundation liver life walks world hepatitis day is on july 28 get the numbers behind hcv bms foundation hepatitis care china india hcvm benefits health research gs-7977 study treatment about developing world virus treatment
Mehr anzeigen